Oxime derivatives of sordaricin as potent antifungal agents
Michael H. Serrano‐Wu(Broad Institute), Balu Balasubramanian(Bristol-Myers Squibb (United States)), Charles E. Mazzucco(Bristol-Myers Squibb (United States)), Terry M. Stickle(Bristol-Myers Squibb (United States)), Denis R. St. Laurent(Bristol-Myers Squibb (United States)), John F. Barrett(Pfizer (United States)), Dolatrai M. Vyas(Bristol-Myers Squibb (United States))
Cited by 25
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239
Identification of Hepatitis C Virus NS5A Inhibitors
|Journal of Virology|2009|196